Pegavision Corporation

TWSE:6491 Stock Report

Market Cap: NT$29.0b

Pegavision Valuation

Is 6491 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6491 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6491 (NT$372) is trading below our estimate of fair value (NT$932.94)

Significantly Below Fair Value: 6491 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6491?

Key metric: As 6491 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 6491. This is calculated by dividing 6491's market cap by their current earnings.
What is 6491's PE Ratio?
PE Ratio14.5x
EarningsNT$2.00b
Market CapNT$29.02b

Price to Earnings Ratio vs Peers

How does 6491's PE Ratio compare to its peers?

The above table shows the PE ratio for 6491 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average19.2x
6782 Visco Vision
20.4x20.7%NT$12.6b
4107 Bioteque
17.5xn/aNT$8.7b
1565 St.Shine OpticalLtd
18x19.2%NT$11.3b
4129 United Orthopedic
20.8xn/aNT$9.5b
6491 Pegavision
14.5x9.2%NT$29.0b

Price-To-Earnings vs Peers: 6491 is good value based on its Price-To-Earnings Ratio (14.5x) compared to the peer average (19.2x).

Price to Earnings Ratio vs Industry

How does 6491's PE Ratio compare vs other companies in the TW Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
6491 14.5xIndustry Avg. 19.5xNo. of Companies9PE01224364860+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 6491 is good value based on its Price-To-Earnings Ratio (14.5x) compared to the TW Medical Equipment industry average (19.5x).

Price to Earnings Ratio vs Fair Ratio

What is 6491's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6491 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio14.5x
Fair PE Ratio16.4x

Price-To-Earnings vs Fair Ratio: 6491 is good value based on its Price-To-Earnings Ratio (14.5x) compared to the estimated Fair Price-To-Earnings Ratio (16.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 6491 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentNT$372.00
NT$440.00
+18.3%
9.3%NT$500.00NT$393.00n/a6
Nov ’25NT$385.00
NT$440.00
+14.3%
10.2%NT$500.00NT$393.00n/a5
Oct ’25NT$439.00
NT$515.60
+17.4%
6.6%NT$576.00NT$475.00n/a5
Sep ’25NT$436.00
NT$520.80
+19.4%
6.5%NT$576.00NT$475.00n/a5
Aug ’25NT$436.50
NT$526.80
+20.7%
7.0%NT$576.00NT$475.00n/a5
Jul ’25NT$484.00
NT$546.80
+13.0%
7.4%NT$600.00NT$500.00n/a5
Jun ’25NT$472.50
NT$529.20
+12.0%
9.4%NT$600.00NT$470.00n/a5
May ’25NT$524.00
NT$518.17
-1.1%
10.0%NT$600.00NT$463.00n/a6
Apr ’25NT$479.00
NT$450.57
-5.9%
15.7%NT$576.00NT$325.00n/a7
Mar ’25NT$396.50
NT$428.86
+8.2%
11.0%NT$470.00NT$325.00n/a7
Feb ’25NT$381.00
NT$422.67
+10.9%
11.4%NT$470.00NT$325.00n/a6
Jan ’25NT$396.50
NT$428.67
+8.1%
12.1%NT$474.00NT$325.00n/a6
Dec ’24NT$399.50
NT$426.29
+6.7%
11.3%NT$474.00NT$325.00n/a7
Nov ’24NT$387.00
NT$444.00
+14.7%
14.6%NT$548.00NT$325.00NT$385.007
Oct ’24NT$389.00
NT$431.67
+11.0%
16.8%NT$548.00NT$315.00NT$439.006
Sep ’24NT$385.00
NT$431.67
+12.1%
16.8%NT$548.00NT$315.00NT$436.006
Aug ’24NT$353.00
NT$417.83
+18.4%
13.1%NT$474.00NT$315.00NT$436.506
Jul ’24NT$345.00
NT$429.00
+24.3%
15.8%NT$530.00NT$310.00NT$484.006
Jun ’24NT$366.00
NT$460.67
+25.9%
9.9%NT$530.00NT$405.00NT$472.506
May ’24NT$434.50
NT$483.17
+11.2%
14.8%NT$550.00NT$355.00NT$524.006
Apr ’24NT$409.50
NT$483.17
+18.0%
14.8%NT$550.00NT$355.00NT$479.006
Mar ’24NT$455.00
NT$475.17
+4.4%
16.9%NT$550.00NT$355.00NT$396.506
Feb ’24NT$464.00
NT$446.00
-3.9%
15.2%NT$530.00NT$355.00NT$381.006
Jan ’24NT$424.00
NT$420.20
-0.9%
14.6%NT$530.00NT$355.00NT$396.505
Dec ’23NT$378.00
NT$385.25
+1.9%
10.6%NT$425.00NT$325.00NT$399.504
Nov ’23NT$281.50
NT$460.00
+63.4%
11.5%NT$550.00NT$420.00NT$387.004

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Universal Vision Biotechnology

NT$18.2b

Operates a chain of eye care clinics in Taiwan and China.

3218

NT$213.00

7D

0.2%

1Y

-27.1%

Pacific Hospital Supply

NT$6.5b

Manufactures, processes, and sells medical disposable products and equipment in Taiwan.

4126

NT$89.00

7D

0.7%

1Y

2.9%

Hi-Clearance

NT$6.2b

Supplies medical devices for the renal, cardiac, radiation, dental, oral surgery, and metabolism markets in Taiwan.

1788

NT$138.50

7D

0%

1Y

1.1%